Melatonin improves cerebrovascular function and decreases oxidative stress in chronically hypoxic lambs

Chronic hypoxia during gestation and delivery results in oxidative stress and cerebrovascular dysfunction in the neonate. We assessed whether melatonin, a potent antioxidant and potential vasodilator, improves the cerebral vascular function in chronically hypoxic neonatal lambs gestated and born in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pineal research 2014-08, Vol.57 (1), p.33-42
Main Authors: Herrera, Emilio A., Macchiavello, Roberto, Montt, Camilo, Ebensperger, Germán, Díaz, Marcela, Ramírez, Santiago, Parer, Julian T., Serón-Ferré, María, Reyes, Roberto V., Llanos, Aníbal J.
Format: Article
Language:English
Subjects:
Animals
cerebral circulation
Cerebrovascular Circulation - drug effects
chronic hypoxia
Hypoxia - drug therapy
melatonin
Melatonin - therapeutic use
neonate
nitric oxide
Nitric Oxide - metabolism
oxidative stress
Oxidative Stress - drug effects
Sheep
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic hypoxia during gestation and delivery results in oxidative stress and cerebrovascular dysfunction in the neonate. We assessed whether melatonin, a potent antioxidant and potential vasodilator, improves the cerebral vascular function in chronically hypoxic neonatal lambs gestated and born in the highlands (3600 m). Six lambs received melatonin (1 mg/kg per day oral) and six received vehicle, once a day for 8 days. During treatment, biometry and hemodynamic variables were recorded. After treatment, lambs were submitted to a graded FiO2 protocol to assess cardiovascular responses to oxygenation changes. At 12 days old, middle cerebral arteries (MCA) were collected for vascular reactivity, morphostructural, and immunostaining evaluation. Melatonin increased fractional growth at the beginning and improved carotid blood flow at all arterial PO2 levels by the end of the treatment (P 
ISSN:0742-3098
1600-079X
DOI:10.1111/jpi.12141